Associations between plasma clozapine/N-desmethylclozapine ratio, insulin resistance and cognitive performance in patients with co-morbid obesity and ultra-treatment resistant schizophrenia

Associations between plasma clozapine/N-desmethylclozapine ratio, insulin resistance and cognitive performance in patients with co-morbid obesity and ultra-treatment resistant schizophrenia

Abstract Clozapine (CLZ), the sole antipsychotic with superior efficacy for ultra-treatment resistant schizophrenia (TRS), is limited by adverse effects, including metabolic dysregulation. Clozapine’s main metabolite, N-desmethylclozapine (NDMC), has potent 5-HT2C antagonist properties which may exp...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kenya A. Costa-Dookhan, Tarek K. Rajji, Veronica N. Tran, Sylvie Bowden, Daniel J. Mueller, Gary J. Remington, Sri Mahavir Agarwal, Margaret K. Hahn
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/4facbfff40714bdaa240ff203aa63723
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/4facbfff40714bdaa240ff203aa63723

Ejemplares similares